[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-361825-en":59,"doc-seo-361825-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},361825,16904993612988,"Olivia Brown","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","BRAF Targeting Across Solid Tumors - Molecular Aspects and Clinical Applications","BRAF mutations drive multiple malignancies including melanoma, colorectal cancer, and non-small-cell lung cancer, with BRAF V600E as the most common actionable alteration. BRAF plus MEK inhibitor therapy has improved progression-free and overall survival in melanoma, yet metastatic colorectal cancer shows poor outcomes and frequent resistance. Resistance is linked to secondary MAPK-pathway changes, activation of PI3K/AKT signaling, and alterations in the tumor microenvironment. Ongoing work explores BRAF inhibitor combinations with immunotherapies, while emphasizing tissue-of-origin context to guide future targeted strategies.","Review  \nBRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications  \nHiba Mechahougui 1, *, James Gutmans 1, Roumaïssa Gouasmi 2, Laure Smekens 1 and Alex Friedlaender 3, *  \nAcademic Editor: Antonio D’Amati  \nReceived: 8 March 2025  \nRevised: 7 April 2025  \nAccepted: 9 April 2025  \nPublished: 16 April 2025  \nCitation: Mechahougui, H.;  \nGutmans, J.; Gouasmi, R.; Smekens, L.; Friedlaender, A. BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications. Int.  \nJ. Mol. Sci. 2025, 26, 3757. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26083757](doi.org/10.3390/ijms26083757)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland; [sam.gutmans@gmail.com](sam.gutmans@gmail.com) (J.G.); [laure.smekens@hug.ch](laure.smekens@hug.ch) (L.S.)  \n2 Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69100 Lyon, France; [roumaissa.gouasmi@lyon.unicancer.fr](roumaissa.gouasmi@lyon.unicancer.fr)  \n3 Clinique Générale Beaulieu, 1206 Geneva, Switzerland  \n* Correspondence: hiba.mechahougui@hug.ch (H.M.); [afriedlaender@beaulieu.ch](afriedlaender@beaulieu.ch) (A.F.)  \nAbstract: BRAF mutations are critical drivers in cancers such as melanoma, colorectal cancer, and non-small-cell lung cancer. The most common mutation, BRAF V600E, is a key therapeutic target. Targeted treatments with BRAF and MEK inhibitors have significantly improved progression-free and overall survival in melanoma patients. However, in cancers like metastatic colorectal cancer, BRAF mutations are associated with poor outcomes due to aggressive disease behavior and resistance to conventional chemotherapy. Despite progress, resistance to BRAF/MEK inhibitors remains a major challenge, often driven by secondary mutations in the mitogen-activated protein kinase (MAPK) pathway, activation of alternative pathways such as phosphoinositide 3-kinases (PI3Ks)/protein kinase B (AKT), or changes in the tumor microenvironment. These challenges have motivated ongoing research into combining BRAF inhibitors with immunotherapies to enhance and prolong treatment effectiveness. Future research must also account for the role of the cancer’s tissue of origin, as the biological context significantly influences response to targeted therapies, highlighting the need for a deeper understanding of tumor biology, micro-environment, and genetics.  \nKeywords: targeted therapy; molecular oncology; precision oncology; tissue specificity; BRAF  \n1. Introduction  \nCancer remains one of the leading causes of morbidity and mortality worldwide [1], driven by a complex interplay of genetic, epigenetic, and environmental factors. Historically, cancer treatment has relied on non-specific modalities such as chemotherapy and radiation, which, while effective in some settings, offer limited precision and are often associated with significant toxicity. Over the past two decades, advances in cancer genomics have reshaped our understanding of tumor biology, paving the way for precision oncology, an approach that seeks to tailor treatment based on the specific molecular alterations driving an individual patient’s tumor. Among the most clinically actionable oncogenicdrivers identified to date is BRAF, a serine/threonine kinase that plays a pivotal role in the MAPK signaling pathway. Initially discovered in melanoma, BRAF mutations have since been identified across a wide spectrum of malignancies, including non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), thyroid cancer, gliomas, other rare cancers, and various hematologic and pediatric tumors. The discovery of t","cbCainYToLUl1Z5Y","https://ap.wps.com/l/cbCainYToLUl1Z5Y","pdf",1084131,25,"English","en",105,"# Abstract\n# Introduction\n# BRAF Biology and Its Therapeutical Implication","[{\"question\":\"Which BRAF mutation is the most common therapeutic target across cancers?\",\"answer\":\"BRAF V600E is identified as the most common mutation and a key therapeutic target.\"},{\"question\":\"How have BRAF/MEK inhibitors affected patient outcomes in melanoma?\",\"answer\":\"Targeted BRAF and MEK inhibitors have significantly improved progression-free and overall survival in melanoma patients.\"},{\"question\":\"What factors contribute to resistance to BRAF/MEK inhibitors?\",\"answer\":\"Resistance can be driven by secondary mutations in the MAPK pathway, activation of alternative PI3K/AKT signaling, and changes within the tumor microenvironment.\"}]","BRAF Targeting Across Solid Tumors - Molecular Aspects and Clinical Applications | PDF",1790145698,63,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d74ebc2f69d3f1b2805f34212a007d24.webp",983,1390,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61cd819531487e5685348046211e4f81.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d6f01494d3fa82debc9b414c178b5cb.webp",981,1387,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3c3977eebf46b3e9f231804da95b85a.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"braf-targeting-across-solid-tumors-molecular-aspects-and-clinical-applications","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/braf-targeting-across-solid-tumors-molecular-aspects-and-clinical-applications/361825/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/braf-targeting-across-solid-tumors-molecular-aspects-and-clinical-applications/361825.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":44},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Which BRAF mutation is the most common therapeutic target across cancers?","Question",{"text":146,"@type":147},"BRAF V600E is identified as the most common mutation and a key therapeutic target.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How have BRAF/MEK inhibitors affected patient outcomes in melanoma?",{"text":151,"@type":147},"Targeted BRAF and MEK inhibitors have significantly improved progression-free and overall survival in melanoma patients.",{"name":153,"@type":144,"acceptedAnswer":154},"What factors contribute to resistance to BRAF/MEK inhibitors?",{"text":155,"@type":147},"Resistance can be driven by secondary mutations in the MAPK pathway, activation of alternative PI3K/AKT signaling, and changes within the tumor microenvironment.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790296383]